Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis
| Autor: | Linda T. Vahdat, Dimitris Bertsimas, John Silberholz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Drug Cancer Research medicine.medical_specialty media_common.quotation_subject Breast Neoplasms law.invention 03 medical and health sciences 0302 clinical medicine Breast cancer Pharmacotherapy Randomized controlled trial law Outcome Assessment Health Care medicine Humans Neoplasm Metastasis Intensive care medicine media_common Neoplasm Staging Clinical Trials as Topic business.industry Disease Management Guideline Health Care Costs medicine.disease Metastatic breast cancer Combined Modality Therapy Clinical trial 030104 developmental biology Oncology 030220 oncology & carcinogenesis Meta-analysis Female business |
| Zdroj: | Springer US |
| Popis: | Purpose Oncologists, clinical trialists, and guideline developers need tools that enable them to efficiently review the settings and results of previous studies testing metastatic breast cancer (MBC) drug therapies. Methods We searched the literature to identify clinical trials testing MBC drug therapies. Key eligibility criteria included at least 90% of patients enrolled in the trial having MBC, therapeutic clinical trials, and Phase II–III studies. Studies were stratified based on patients’ tumor receptor statuses and prior exposure to therapy. Survival and toxicity of each drug therapy were estimated from randomized controlled trials using network meta-analysis and from all studies using meta-analysis. These results, along with estimated drug costs, are presented in a web-based visualization tool. Results We included 1865 studies containing 2676 treatment arms and 184,563 patients in the tool ( http://www.cancertrials.info ). Meta-analysis-based efficacy and toxicity estimates are available for 85 HER-2-directed therapies, 84 hormonal therapies, and 442 undirected therapies. Network meta-analysis-based estimates are available for 16 HER-2-directed therapies, 26 hormonal therapies, and 131 undirected therapies. Conclusions In this era of increasing choices of MBC therapeutic agents and no superior approach to choosing a treatment regimen, the ability to compare multiple therapies based on survival, toxicity and cost would enable treating physicians to optimize therapeutic choices for patients. For investigators, it can point them in research directions that were previously non-obvious and for guideline designers, enable them to efficiently review the MBC clinical trial literature and visualize how regimens compare in the key dimensions of clinical benefit, toxicity, and cost. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|